Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
about
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Intractable and highly active relapsing multiple sclerosis - role of alemtuzumabTargeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificityHuman peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab.The evolving role of alemtuzumab (Campath-1H) in renal transplantation.Cell death signaling and anticancer therapyVariable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapyUpdate on the therapy of highly aggressive non-Hodgkin's lymphoma.Alemtuzumab in CLL and other lymphoid neoplasms.Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational useEffect of alemtuzumab on intestinal intraepithelial lymphocytes and intestinal barrier function in cynomolgus modelAlemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancerPost-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeysRediscovering alemtuzumab: current and emerging therapeutic roles.Antibody-based therapy of leukaemia.Alemtuzumab and multiple sclerosis: therapeutic application.Infections associated with monoclonal antibody and fusion protein therapy in humans.Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis.Drugs in development for relapsing multiple sclerosis.Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy.Targeted therapy for chronic lymphocytic leukemia: current status and future directions.The role of T cells in the microenvironment of Hodgkin lymphoma.The immunological function of CD52 and its targeting in organ transplantation.Use of polyclonal/monoclonal antibody therapies in transplantation.Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes.Seasonal changes of lower respiratory tract infections in lung transplant recipients during the first post-transplant year: The Hungarian experience.Alemtuzumab in allogeneic hematopoetic stem cell transplantation.CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies.Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review.Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
P2860
Q26768154-BA64CCA0-31AA-4C0A-94CC-B19ED8703A5BQ26783585-981FFC4D-16DA-4999-BDBD-C76697119463Q33415472-02CA3892-AF66-4FDB-BF38-0A60894C16FAQ34326110-6C3818C1-CA58-4369-B966-F1AFD52C464EQ34595224-891AECC4-AD41-4EE2-A71A-44A2522B3B83Q34613973-9E4B4C3E-F43D-4692-9C0E-2ED88E7A676DQ35972102-78C85CE1-D36C-4536-A22D-DA61A10EB2EBQ36365590-746F9A02-F4FB-4CD6-9007-DE15B7AFB84EQ36521840-FB65A0D0-C072-4F29-8FB4-47920A4662D7Q36659824-1F8A6A4A-4F41-4F75-9A52-B6E026E8C3B6Q36768605-3C1154FC-1EE5-4C1D-BDF9-81180A882DDAQ36807186-0D8D7C51-D9D2-45AC-9020-99DE96F03B59Q36832113-1868C31A-372C-43B3-9D62-7271932AF20CQ36986787-9E1A32DA-7A13-4BDA-AFA7-D32F383E45E1Q37246401-D105D114-79EA-4E3A-B0F4-182353FB11B9Q37362699-9A49B24A-2CDE-4A7B-A755-8776AC64AF78Q37381758-64316F20-23B3-49F5-A2C7-04943DF34850Q37605247-CBB02F86-A2E8-4097-AFB6-E3FD3F16DC1CQ37679919-DCEE08D0-7061-4CF2-8FCA-987706B1F21EQ37912944-716157EC-3D95-42E6-96F6-7C207851E1B6Q37929621-EBAF76FB-6C63-4039-940D-5FDB49CB9124Q38101004-E61E1B04-7568-4F86-9B76-6B1A4460D883Q38173374-CD7BC176-6949-4F61-AA40-530E4CBA55F8Q38187176-FA19A3FD-802B-4466-8DFD-DDC39FD04483Q38331701-CEB51CF3-097F-4031-B245-584CD7FE4C85Q38576547-A1473FC9-853C-4A72-9ADC-D5D3F48274B1Q38747419-033BE289-5F64-41F6-9559-B4EAB1F4F43DQ38769922-E2F16834-57FC-4002-8730-6B002868EC44Q39474069-C1AFA69A-9A4A-46B9-859F-F1824A083526Q40344121-40360089-0206-4140-8C38-B95286CD166EQ42149544-4B6F9DC9-9BAB-45A2-B4EF-612E96705D62Q47697902-3B33162F-614E-4D4B-A9AB-A0BB2AA2C051Q50089138-EC116988-5D3A-40FC-BF5D-7B9DDEEEC3BDQ51756510-85308E89-7F64-45F6-B02A-BA9F6DBB2CACQ51774121-645DFEDF-5F2D-46AD-866A-C773FCDCC27E
P2860
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Alemtuzumab induces enhanced a ...... pendent cellular cytotoxicity.
@en
Alemtuzumab induces enhanced a ...... pendent cellular cytotoxicity.
@nl
type
label
Alemtuzumab induces enhanced a ...... pendent cellular cytotoxicity.
@en
Alemtuzumab induces enhanced a ...... pendent cellular cytotoxicity.
@nl
prefLabel
Alemtuzumab induces enhanced a ...... pendent cellular cytotoxicity.
@en
Alemtuzumab induces enhanced a ...... pendent cellular cytotoxicity.
@nl
P2093
P921
P1476
Alemtuzumab induces enhanced a ...... ependent cellular cytotoxicity
@en
P2093
Alexander Röth
Holger Nückel
Ulrich Dührsen
Winfried Siffert
P304
P356
10.1016/J.EJPHAR.2005.03.024
P407
P577
2005-05-01T00:00:00Z